← Eichor
Condition: Neoplasm Plasma Cell Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neoplasm Plasma Cell

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Activity Levels in Bone Marrow Transplant Patients
Phase N/A · 1 location(s) · Michael Tomasson · NCT04115241Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · University of Rochester · NCT05597345A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomi
Phase 2 · 16 location(s) · Karyopharm Therapeutics Inc · NCT04414475A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or R
Phase 3 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07452198AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06561854Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
Phase N/A · 1 location(s) · The Royal Wolverhampton Hospitals NHS Trust · NCT04234022Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Phase 2 · 1 location(s) · Stanford University · NCT06461988Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05776979Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Phase 2 · 29 location(s) · European Myeloma Network B.V. · NCT07107529Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With R
NA · 1 location(s) · Beijing Boren Hospital · NCT06983951All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06158412A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an
Phase 2 · 5 location(s) · GlaxoSmithKline · NCT07224672Discontinuation Study
NA · 1 location(s) · University College Cork · NCT05866757Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-
Phase 2 · 1 location(s) · Carl Ola Landgren, MD, PhD · NCT06100237A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07454382In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia
Phase N/A · 7 location(s) · Carevive Systems, Inc. · NCT05974150Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
NA · 3 location(s) · University of Miami · NCT05745285A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirector
Phase N/A · 68 location(s) · Janssen-Cilag Ltd. · NCT06285318Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery
NA · 1 location(s) · AC Camargo Cancer Center · NCT07268846Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Thera
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06140966FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethas
Phase 3 · 38 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT06187441A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
EARLY_Phase 1 · 4 location(s) · Suzhou Immunofoco Biotechnology Co., Ltd · NCT07493135Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
NA · 14 location(s) · Fundación Instituto de Estudios de Ciencias de la Salud de C · NCT03711110A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07255898
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.